Oishi S, Shimada T, Tajiri J, Inoue J, Sato T
Acta Endocrinol (Copenh). 1984 Dec;107(4):476-81. doi: 10.1530/acta.0.1070476.
Serum calcitonin was measured by radioimmunoassay (RIA) in 63 patients with hyperthyroidism, 37 with hypothyroidism, 9 with surgically proven medullary thyroid carcinoma (MTC) and 81 normal subjects. Provocative tests of calcitonin by calcium infusion were performed in 11 with hyperthyroidism, 10 with hypothyroidism, 6 with MTC and 14 normal subjects. Changes of calcitonin were also studied before and after treatment in 17 patients with hyperthyroidism and 12 with hypothyroidism. The basal calcitonin levels were increased in both hyperthyroidism (117 +/- 60.1 pg/ml (mean +/- SD): n = 63, P less than 0.001) and hypothyroidism (137 +/- 107 pg/ml, n = 37, P less than 0.001), and significantly increased in MTC 14 765 +/- 25 039 pg/ml, range 390 to 70 400 pg/ml, n = 9, P less than 0.001) compared with those in normal subjects (45.8 +/- 22.3 pg/ml, n = 81). Increases of calcitonin during calcium load (iv 4.5 mg calcium/kg for 10 min) were significantly lower in both hyperthyroidism and hypothyroidism patients than in those in MTC. The calcitonin levels were not correlated with the serum T3, T4, TSH concentrations or titres of serum antithyroid antibodies in hyperthyroidism and hypothyroidism. We found some tendency toward decreasing calcitonin levels with the euthyroid state after treatment in both groups, but the changes were not significant. Although exact mechanisms of increased calcitonin in hyperthyroidism and hypothyroidism were not clear, our findings suggest that a 2- to 3-fold elevation of calcitonin levels in these patients did not indicate malignancy; MTC could be readily differentiated by a calcium infusion test.
采用放射免疫分析法(RIA)检测了63例甲状腺功能亢进患者、37例甲状腺功能减退患者、9例经手术证实的甲状腺髓样癌(MTC)患者及81名正常受试者的血清降钙素。对11例甲状腺功能亢进患者、10例甲状腺功能减退患者、6例MTC患者及14名正常受试者进行了钙输注激发降钙素试验。还研究了17例甲状腺功能亢进患者和12例甲状腺功能减退患者治疗前后降钙素的变化。甲状腺功能亢进患者(117±60.1 pg/ml(均值±标准差):n = 63,P<0.001)和甲状腺功能减退患者(137±107 pg/ml,n = 37,P<0.001)的基础降钙素水平均升高,与正常受试者(45.8±22.3 pg/ml,n = 81)相比,MTC患者(14 765±25 039 pg/ml,范围390至70 400 pg/ml,n = 9,P<0.001)的基础降钙素水平显著升高。甲状腺功能亢进和甲状腺功能减退患者在钙负荷(静脉注射4.5 mg钙/kg,持续10分钟)期间降钙素的升高明显低于MTC患者。甲状腺功能亢进和甲状腺功能减退患者的降钙素水平与血清T3、T4、TSH浓度或血清抗甲状腺抗体滴度无关。我们发现两组患者治疗后甲状腺功能正常状态下有降钙素水平下降的趋势,但变化不显著。虽然甲状腺功能亢进和甲状腺功能减退时降钙素升高的确切机制尚不清楚,但我们的研究结果表明,这些患者降钙素水平升高2至3倍并不表明有恶性肿瘤;通过钙输注试验可以很容易地鉴别出MTC。